XELJANZ 5 MG TABLET

What it is

XELJANZ 5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as tofacitinib, under the trade name “XELJANZ”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Pfizer Laboratories Div Pfizer Inc.

FDA’s Established Pharmacologic Class for it is Janus Kinase Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00069-1001-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,213.15 for 30 tablets (30 × $73.77164 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $0.57264 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-02 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · Why 30 tablets · NADAC explanation codes

The NDC

• 00069-1001-01 · Pfizer Laboratories Div Pfizer Inc · $73.77164 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

4 other products in the NADAC file share the FDA nonproprietary name tofacitinib with XELJANZ 5 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-02, 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $73.77164 per EA filed.

Of the 10 other products in FDA’s Janus Kinase Inhibitor class priced per EA, 8 have a higher middle NADAC price and 2 a lower one. The one in the middle is OLUMIANT 4 MG TABLET, at $184.66233 per EA filed (eff. 2026-01-01).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $2,810.48 for 30 tablets, at an average of $93.68269 per EA in 2024 (2024-01-01 to 2024-12-31) for “Xeljanz” and “Tofacitinib Citrate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 48,637 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: TOFACITINIB 5 MG TABLET. Ask your pharmacist or prescriber; do not switch on your own.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.